Developer docs
API playgroundTry for free, no card

Search company profiles

QDX

Full company profile

uuid0026ewa

Namestring
QDX
Legal namestring
QDX
Websiteurl
qdx.co
Company typeenum
Private
Founded yearint
2023
Descriptiontext

QDX is a Singapore-based software company founded in 2023 that develops quantum chemistry simulation technology for drug discovery and materials science applications. Its core product, EXESS, is a proprietary quantum chemistry engine that performs over 1 quintillion calculations per second and operates 3,000 to 4,000 times faster than competing software without requiring quantum computing hardware, enabling large molecule calculations that were previously computationally infeasible. The engine applies optimization and generative AI techniques to predict molecular configurations and accelerate identification of drug candidates.

QDX operates a sales-led, enterprise-focused go-to-market targeting pharmaceutical and biotechnology companies through direct strategic partnerships and co-development agreements rather than traditional product distribution. Its primary customer segment is pharma/biotech firms seeking to compress drug discovery timelines. The company's revenue model appears to be licensing/royalty-based, tied to the progression of partnered drug programs. Its partnership with Prelude Therapeutics to study JAK2 V617F mutant-selective inhibitors for myeloproliferative neoplasms resulted in Incyte's acquisition of that program for up to $910 million, providing external validation of QDX's scientific and commercial approach. The company is privately held, employs 11-50 people, and is led by founder/CEO Loong Wang.

Short descriptiontext

QDX is a Singapore-based quantum chemistry software company whose EXESS engine performs over 1 quintillion molecular calculations per second for pharmaceutical and biotech drug discovery partners. The company serves pharma and biotech firms via licensing and strategic co-development agreements, with Prelude Therapeutics and the Incyte $910M acquisition as key validation signals.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSingapore, Singapore
HQ citystring
Singapore
HQ countrystring
Singapore
HQ regionstring
Asia
Markets served

Serves global market

Keyword5 values
quantum chemistry software, drug discovery simulation, molecular modeling platform, computational chemistry engine, pharma R&D software
Industry3 codes
PRIMARYHDAGAEAB
Pharmaceutical & Biotech R&D Simulation (drug discovery, protein/ligand)
Hardware, Technology & Telecom/Quantum Computing/Quantum Simulation & Digital Twins
SECONDARYHDAGAMAG
Quantum Simulation (Physics/Chemistry/Materials) Research
Hardware, Technology & Telecom/Quantum Computing/Quantum Research & Development (Academic and Industry Research)
SECONDARYHDAGADAC
Quantum Machine Learning (QML)
Hardware, Technology & Telecom/Quantum Computing/Quantum Algorithms & Application Development
NAICS code2 codes
  • Software Publishers5132
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Computer Programming Services7371
Product category
Computational Chemistry / Drug Discovery Software
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Quantum Chemistry Simulation Services
TypeLicensing Royalties
Description

QDX provides quantum chemistry simulation technology to pharmaceutical and biotech partners for drug discovery applications. Revenue appears to come from strategic partnerships and co-development agreements with drug companies.

rdworldonline.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

QDX develops and licenses EXESS, a proprietary quantum chemistry simulation engine that performs over 1 quintillion calculations per second on classical computing infrastructure. The platform enables pharmaceutical and biotech researchers to run large-molecule calculations 3,000 to 4,000 times faster than competing quantum chemistry software without requiring quantum computing hardware, accelerating drug discovery and materials science research.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Performs over 1 quintillion calculations per second
+1 more record
Product overview1 text field

QDX offers a single core product: EXESS, an ultrafast quantum chemistry engine designed specifically for drug discovery applications. The platform enables pharmaceutical researchers to perform large-scale molecular calculations at speeds 3,000 to 4,000 times faster than conventional software, without the need for quantum computing infrastructure.

Product and service1 record
1EXESS Quantum Chemistry Engine
CategoryComputational Chemistry / Drug Discovery Software
Description

EXESS is an ultrafast proprietary quantum chemistry simulation engine for pharmaceutical and biotechnology researchers, performing over 1 quintillion calculations per second on classical infrastructure and enabling large-molecule calculations 3,000 to 4,000 times faster than competing software for drug discovery and materials science applications.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-04
Description

QDX partnered with Prelude Therapeutics to apply quantum chemistry simulations to cancer drug discovery. The collaboration focused on studying structural differences in JAK2 V617F mutant proteins to develop selective inhibitors for treating myeloproliferative neoplasms (MPNs). This partnership resulted in Prelude's JAK2V617F program being acquired by Incyte for up to $910 million, validating the scientific approach.

Strategic tierMinorTypeOthers
Description

Incyte acquired Prelude's JAK2V617F program, which was developed using QDX's quantum chemistry simulations. While not a direct partnership with QDX, Incyte's $910M acquisition validates the effectiveness of QDX-enabled drug discovery.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Schrödinger provides computational chemistry and molecular simulation software widely used in pharma drug discovery. It is the most established direct competitor to QDX in quantum chemistry and molecular simulation software for pharmaceutical R&D.

TypeDirect peer
Description

Multiverse Computing applies quantum and quantum-inspired algorithms to pharma, materials, and finance. Its Singularity/Quantum Pharma tools overlap directly with QDX's pharma drug discovery simulation use case.

TypeDirect peer
Description

QC Ware builds quantum and quantum-inspired software for chemistry, materials, and machine learning, with a similar pharma/biotech customer focus to QDX.

TypeEmerging player
Description

Zapata AI develops quantum-inspired generative AI and optimization algorithms for enterprise use cases including pharma and materials, making it a partial overlap with QDX's quantum chemistry simulation plus generative AI stack.

TypeEmerging player
Description

Xanadu builds photonic quantum hardware and the PennyLane software platform for quantum chemistry and quantum machine learning, overlapping with QDX's drug discovery and QML capability areas.

TypeBroad incumbent
Description

Google Quantum AI develops superconducting quantum hardware and has published landmark quantum chemistry simulations. It represents the long-term hardware-based competitive threat to QDX's classical approach.

7QunaSys
TypeDirect peer
Description

QunaSys develops quantum chemistry algorithms and software (Qamuy, etc.) for chemical and pharmaceutical applications. It is a direct competitor to QDX in applying quantum algorithms to drug discovery and materials science.

TypeBroad incumbent
Description

Quantinuum combines trapped-ion quantum hardware (H-Series) with chemistry simulation software (InQuanto). It is a broader quantum computing incumbent competing with QDX in the quantum chemistry for pharma space.

TypeBroad incumbent
Description

PsiQuantum is pursuing fault-tolerant photonic quantum computing, with chemistry simulations as a key target application. It represents a longer-term competitive force for the broader quantum chemistry simulation market.

TypeBroad incumbent
Description

IBM Quantum offers quantum hardware and Qiskit-based chemistry tools widely used in pharma R&D. It is a broad incumbent in the quantum chemistry space where QDX competes with a classical-algorithm alternative.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

QDX

Computational Chemistry / Drug Discovery Softwareqdx.co

QDX is a Singapore-based quantum chemistry software company whose EXESS engine performs over 1 quintillion molecular calculations per second for pharmaceutical and biotech drug discovery partners. The company serves pharma and biotech firms via licensing and strategic co-development agreements, with Prelude Therapeutics and the Incyte $910M acquisition as key validation signals.

What QDX does

QDX is a Singapore-based software company founded in 2023 that develops quantum chemistry simulation technology for drug discovery and materials science applications. Its core product, EXESS, is a proprietary quantum chemistry engine that performs over 1 quintillion calculations per second and operates 3,000 to 4,000 times faster than competing software without requiring quantum computing hardware, enabling large molecule calculations that were previously computationally infeasible. The engine applies optimization and generative AI techniques to predict molecular configurations and accelerate identification of drug candidates.

QDX operates a sales-led, enterprise-focused go-to-market targeting pharmaceutical and biotechnology companies through direct strategic partnerships and co-development agreements rather than traditional product distribution. Its primary customer segment is pharma/biotech firms seeking to compress drug discovery timelines. The company's revenue model appears to be licensing/royalty-based, tied to the progression of partnered drug programs. Its partnership with Prelude Therapeutics to study JAK2 V617F mutant-selective inhibitors for myeloproliferative neoplasms resulted in Incyte's acquisition of that program for up to $910 million, providing external validation of QDX's scientific and commercial approach. The company is privately held, employs 11-50 people, and is led by founder/CEO Loong Wang.

QDX firmographics

Firmographics
Name
QDX
Legal name
QDX
Website
https://qdx.co
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
11–50 employees
Short description
QDX is a Singapore-based quantum chemistry software company whose EXESS engine performs over 1 quintillion molecular calculations per second for pharmaceutical and biotech drug discovery partners. The company serves pharma and biotech firms via licensing and strategic co-development agreements, with Prelude Therapeutics and the Incyte $910M acquisition as key validation signals.
Ownership category
akta.pro rank

QDX industry classification

Industry
Product category
Computational Chemistry / Drug Discovery Software
NAICS
Software Publishers (5132), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Computer Programming Services (7371)
akta.pro industry
PRIMARYHDAGAEAB
Pharmaceutical & Biotech R&D Simulation (drug discovery, protein/ligand)
Hardware, Technology & Telecom/Quantum Computing/Quantum Simulation & Digital Twins
SECONDARYHDAGAMAG
Quantum Simulation (Physics/Chemistry/Materials) Research
Hardware, Technology & Telecom/Quantum Computing/Quantum Research & Development (Academic and Industry Research)
SECONDARYHDAGADAC
Quantum Machine Learning (QML)
Hardware, Technology & Telecom/Quantum Computing/Quantum Algorithms & Application Development

Keywords

  • Quantum chemistry software
  • Drug discovery simulation
  • Molecular modeling platform
  • Computational chemistry engine
  • Pharma R&D software

Where QDX is headquartered

Location

Headquarters

HQ city
Singapore
HQ country
Singapore
HQ region
Asia

Markets served

QDX business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Quantum Chemistry Simulation Services: QDX provides quantum chemistry simulation technology to pharmaceutical and biotech partners for drug discovery applications. Revenue appears to come from strategic partnerships and co-development agreements with drug companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

QDX product offering

Product offering

Core offering

QDX develops and licenses EXESS, a proprietary quantum chemistry simulation engine that performs over 1 quintillion calculations per second on classical computing infrastructure. The platform enables pharmaceutical and biotech researchers to run large-molecule calculations 3,000 to 4,000 times faster than competing quantum chemistry software without requiring quantum computing hardware, accelerating drug discovery and materials science research.

Product overview

QDX offers a single core product: EXESS, an ultrafast quantum chemistry engine designed specifically for drug discovery applications. The platform enables pharmaceutical researchers to perform large-scale molecular calculations at speeds 3,000 to 4,000 times faster than conventional software, without the need for quantum computing infrastructure.

Differentiator

Problem solved

Functional benefit

Products and services

  • EXESS Quantum Chemistry Engine EXESS is an ultrafast proprietary quantum chemistry simulation engine for pharmaceutical and biotechnology researchers, performing over 1 quintillion calculations per second on classical infrastructure and enabling large-molecule calculations 3,000 to 4,000 times faster than competing software for drug discovery and materials science applications.

Quantifiable outcome

  • Performs over 1 quintillion calculations per second
  • +1 more outcomes

Companies that use QDX

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

QDX technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature1 record

QDX partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • Prelude TherapeuticscoreStrategic or Co-development Partner · 4 December 2025QDX partnered with Prelude Therapeutics to apply quantum chemistry simulations to cancer drug discovery. The collaboration focused on studying structural differences in JAK2 V617F mutant proteins to develop selective inhibitors for treating myeloproliferative neoplasms (MPNs). This partnership resulted in Prelude's JAK2V617F program being acquired by Incyte for up to $910 million, validating the scientific approach.
  • IncyteminorOthersIncyte acquired Prelude's JAK2V617F program, which was developed using QDX's quantum chemistry simulations. While not a direct partnership with QDX, Incyte's $910M acquisition validates the effectiveness of QDX-enabled drug discovery.

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

QDX competitors and assessment

Company assessment

Direct peers

  • Schrödinger: Schrödinger provides computational chemistry and molecular simulation software widely used in pharma drug discovery. It is the most established direct competitor to QDX in quantum chemistry and molecular simulation software for pharmaceutical R&D.
  • Multiverse Computing: Multiverse Computing applies quantum and quantum-inspired algorithms to pharma, materials, and finance. Its Singularity/Quantum Pharma tools overlap directly with QDX's pharma drug discovery simulation use case.
  • QC Ware: QC Ware builds quantum and quantum-inspired software for chemistry, materials, and machine learning, with a similar pharma/biotech customer focus to QDX.
  • QunaSys: QunaSys develops quantum chemistry algorithms and software (Qamuy, etc.) for chemical and pharmaceutical applications. It is a direct competitor to QDX in applying quantum algorithms to drug discovery and materials science.

Emerging players

  • Zapata AI: Zapata AI develops quantum-inspired generative AI and optimization algorithms for enterprise use cases including pharma and materials, making it a partial overlap with QDX's quantum chemistry simulation plus generative AI stack.
  • Xanadu: Xanadu builds photonic quantum hardware and the PennyLane software platform for quantum chemistry and quantum machine learning, overlapping with QDX's drug discovery and QML capability areas.

Broad incumbents

  • Google Quantum AI: Google Quantum AI develops superconducting quantum hardware and has published landmark quantum chemistry simulations. It represents the long-term hardware-based competitive threat to QDX's classical approach.
  • Quantinuum: Quantinuum combines trapped-ion quantum hardware (H-Series) with chemistry simulation software (InQuanto). It is a broader quantum computing incumbent competing with QDX in the quantum chemistry for pharma space.
  • PsiQuantum: PsiQuantum is pursuing fault-tolerant photonic quantum computing, with chemistry simulations as a key target application. It represents a longer-term competitive force for the broader quantum chemistry simulation market.
  • IBM Quantum: IBM Quantum offers quantum hardware and Qiskit-based chemistry tools widely used in pharma R&D. It is a broad incumbent in the quantum chemistry space where QDX competes with a classical-algorithm alternative.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights5 records

Customer concentration

QDX financial estimates

Financial estimate

Revenue estimate

Valuation estimate

QDX leadership team

Management profile

Number of profiles

Profiles1 record

QDX funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

QDX M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about QDX

What does QDX do?

QDX develops and licenses EXESS, a proprietary quantum chemistry simulation engine that performs over 1 quintillion calculations per second on classical computing infrastructure. The platform enables pharmaceutical and biotech researchers to run large-molecule calculations 3,000 to 4,000 times faster than competing quantum chemistry software without requiring quantum computing hardware, accelerating drug discovery and materials science research.

Is QDX a public or private company?

QDX is a private company. It is classified as unknown and is currently operating.

When was QDX founded?

QDX was founded in 2023. It employs 11 to 50 people.

Where is QDX based?

QDX is headquartered in Singapore, Singapore, in the Asia region.

How does QDX make money?

One revenue line is on record: quantum Chemistry Simulation Services.

Who are QDX's main competitors?

Direct peers on record are Schrödinger, Multiverse Computing, QC Ware and QunaSys. Emerging players are Zapata AI and Xanadu. Broad incumbents are Google Quantum AI, Quantinuum, PsiQuantum and IBM Quantum.

Does QDX have an API?

No public API is recorded for QDX.

What industry is QDX in?

QDX's product category is Computational Chemistry / Drug Discovery Software. Its primary akta.pro industry code is HDAGAEAB, Pharmaceutical & Biotech R&D Simulation (drug discovery, protein/ligand), with a secondary code of HDAGAMAG, Quantum Simulation (Physics/Chemistry/Materials) Research. Its NAICS code is 5132 and its SIC code is 7371.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
livescience.comUltrafast quantum chemistry engine could speed up the development of new medicines and materialsA new quantum chemistry engine called EXESS, developed by QDX, can perform over 1 quintillion calculations per second and significantly speeds up drug discovery and materials science research. The system operates 3,000 to 4,000 times faster than other software without requiring quantum computing, enabling large molecule calculations that were previously infeasible.RdworldonlineHow Prelude and QDX are using quantum chemistry to discover cancer treatmentsPrelude Therapeutics announced preclinical results for its JAK2V617F mutant-selective inhibitors and revealed a partnership with QDX to utilize quantum chemistry simulations for further drug discovery. Concurrently, Incyte agreed to acquire the inhibitor program from Prelude in a deal potentially worth up to $910 million, which extends Prelude's cash runway into 2027 or later. This transaction marks a strategic shift for Prelude as it pauses clinical development of its SMARCA2 degrader programs to focus on the JAK2 and KAT6A programs.DrugdiscoverynewsQuantum chemistry meets cancer treatmentQDX and Prelude Therapeutics are developing drugs that target the JAK2 V617F mutation associated with myeloproliferative neoplasms, a rare blood cancer. The collaboration involves advanced quantum simulations to create mutant-specific inhibitors and a development deal with Incyte, which could be valued up to $910 million.PR NewswireQDX Announces Collaboration with Prelude Therapeutics on Novel Oncology ProgramsQDX announced a collaboration with Prelude Therapeutics to target previously undrugged oncology targets using advanced computational drug discovery techniques. This partnership aims to leverage QDX's quantum mechanical simulation technology and AI to develop new treatments for challenging oncology areas. Both companies express optimism about the potential of this collaboration to advance drug discovery processes.